BRCA2 and breast cancer: 15 BRCA1 and 7 BRCA2 stage III breast cancers were treated by anthracycline-based neoadjuvant therapy. cCR in 6/15 (40%) and 1/7 (14%), pCR in 2/15 (13%) and 0 patients, respectively.